Revlimid (lenalidomide)* | Multiple myeloma 25 mg PO QD on Days 1-21 of repeated 28-day cycles. Recommended dose of dexamethasone is 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg/day PO on Days 1-4 every 28 days | 40 mg/day |
Velcade (bortezomib) | Multiple myeloma (untreated) 1.3 mg/m2/dose in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles. In Cycles 1-4, Velcade is administered SC or IV BIW (days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, Velcade is administered SC or IV QWk (days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of Velcade Multiple myeloma (relapsed) 1.3 mg/m2/dose SC or IV BIW for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, Velcade may be administered on the standard schedule or on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35). At least 72 hours should elapse between consecutive doses of Velcade. | 1.3 mg/m2/dose |